Rebirth of the God-level Xueba

As far as Northern United Pharmaceuticals is concerned, there is still some value. ranwen

Tens of thousands of acres of land have just been acquired, not counting the tens of thousands of skilled workers, nor can they be simply regarded as a burden, after all, they are all skilled workers.

However, the reality is that China in the 1980s had no shortage of skilled workers. So many workers in the small third-tier and major third-tier industries are about to lose their jobs. If it weren’t for the formation of the Chemical Medicine Revitalization Office and the Northern United Pharmaceutical Industry, the tens of thousands of workers in the North China Pharmaceutical Industry would face unemployment within a few years.

To be more precise, the tens of thousands of workers mixed together are like a pile of unsorted dates. If the mess is not scattered, the rotten dates will rot the good ones sooner or later.

No one expected that such Northern United Pharmaceuticals could be valued at 60 million U.S. dollars, and then receive real money from Zeneca.

For Zeneca, whether it is Northern United Pharmaceuticals or the Chemical Drug Promotion Office, they are not interested. The only thing they are interested in is the medicine in Yang Rui's hand.

Just the profits from production and sales will allow them to earn back their capital.

Only the new drug developed by Yang Rui can earn them back 30 million US dollars.

It is difficult for workers in other industries to understand the desire of pharmaceutical companies for new drugs.

There are thousands of pharmaceutical companies in the world, and the number of pharmaceutical companies capable of developing new drugs is usually within a hundred. Except for the single-digit generic drug companies, the remaining double-digit pharmaceutical companies can only enter the market three times a year. Five pure new drugs.

At this time, whoever controls the new medicine simply holds the power of life and death.

Not in a symbolic sense, but in actual life and death.

Like Gaucher disease, although it is a rare disease, it is also a rare disease with a high incidence rate. There are hundreds of thousands of patients in the world, but in the absence of suitable drugs, the life cycle of Gaucher patients Since the onset of the disease, it has only been 10 years, basically no more than 20 years.

At this time, there is also a piece of information that no one wants to think about quietly. If there is a special medicine, there will not be only hundreds of thousands of Gaucher patients in the world.

And with so many people, it is obviously impossible to get medicines at once.

Even from the perspective of safety, countries will not allow new drugs to be spread in their own countries in one go.

At this time, pharmaceutical companies actually control the life and death of these Gaucher patients.

Gaucher patients in whichever country they apply for sales first will be treated first, which not only means a higher survival rate, but also means less pain and improved quality of life.

No one wants to drag a sick body to live.

From the perspective of consumers and hospitals, they also expect specific drugs to appear.

Pharmaceutical companies that can always produce new and good drugs will be more welcomed by hospitals and doctors, which is unique to pharmaceutical companies. When necessary, pharmaceutical companies can even carry out bundled sales, stipulating that as many specific drugs as they buy, they have to buy as many ordinary drugs...

Where laws and regulations are not strict, whoever holds the power of life and death is entitled to make money.

How much is 500,000 human lives worth?

Is $100 a person much?

Is $200 a person expensive?

In the modern consumption system, the production cost is only a small head for pharmaceutical companies, and the sales, research and development and administrative costs are the most expensive places.

A new drug may not make a pharmaceutical company rich in one go. Blockbusters with annual sales of 1 billion US dollars are rare after all. However, a steady stream of new drugs is the meaning of survival for pharmaceutical companies.

Not only the meaning of the pharmaceutical company's own existence, but also the perception of it by the public, society and the country.

If a pharmaceutical company fails to produce a new drug in five years, regardless of whether it makes or buys it, investors will always worry about it even if it earns a lot in other income.

If a pharmaceutical company cannot produce a new drug in 10 years, even if the investors do not say it, the company itself will not be able to survive.

In an industry that sells health and life, there are simply too many ways for pharmaceutical companies to make money.

For some special rare drugs, the annual treatment cost can even reach millions of dollars, which can be called abnormal. Pharmaceutical companies in war-torn regions have never been kind. The pharmaceutical companies in the bustling cities are even more adept at doing business.

However, no matter how pharmaceutical companies try to make money, you have to have drugs in your hands first.

New drugs with a patent period of 15 years and rare drugs with a patent period of 25 years are the weapons in the hands of pharmaceutical companies.

What a 15-year-old boy is willing to pay for his Rogue weapon is what a pharmaceutical company is willing to pay for a new drug.

Under the pressure of Zeneca, the small thinking of Northern United Pharmaceuticals disappeared without a trace like ice and snow falling on the oven.

However, the funds allocated to the account of the ion channel laboratory in advance are still only a pitiful 200,000 US dollars.

In the words of Comrade Wang Gaohan, the new general manager of Northern United Pharmaceuticals: "Use it first, if it is not enough, then say hello, and the money will come."

The project team in charge of recombining DNA naturally complained, and Gu Qiang complained even more: "200,000 US dollars is not even enough to buy a fluorescent microplate reader. You don't need to start, it's over."

The specific medicine for Gaucher disease that Yang Rui chose is an enzyme replacement plan, which is to supplement enzymes for those who lack enzymes. It's as simple as that.

However, it is extremely difficult to make glucocerebrosidase suitable for human body and no matter how this step is carried out, an instrument such as a fluorescent microplate reader is a must.

Glucocerebrosidase is invisible to the human eye.

In addition, higher-resolution UV-visible spectrophotometers, new electrophoresis instruments with higher efficiency, etc., are also essential expenses.

Although laboratories can share these commonly used equipment, it is obviously not the right choice to grab equipment during the tight time of new drug development.

In addition, the scale of the ion channel laboratory is expanding day by day, and it is inevitable to add new instruments to develop new projects, even if they are repeated instruments. It's like the simplest microscope, you can't have a group of lab dogs waiting in line to use it.

Some project teams in China are so poor that they can’t help it. Yang Rui is not going to let the ion channel laboratory live the hard life of queuing up for instruments at two o’clock in the morning.

Who loves who passes.

"Take the money from the laboratory's general ledger, and give them back the 200,000 U.S. dollars." Yang Rui quickly made a decision, then called Xu Zhengping, and said, "You go to contact a foreign evaluation company and ask for our current restructuring. The dna project team, the alternative plan of glucocerebrosidase, conducts price evaluation."

"What is that?" Xu Zhengping was taken aback.

"It's just to find a foreigner's company and let them see how much the things made by our project team are worth in the market." Yang Rui paused, and said: "The people in Northern United Pharmaceuticals are used to living in state-owned enterprises, and they don't want to buy them. Thinking about the cost price to get the research results. 200,000? 2 million is just a raise."

Xu Zhengping went to look for it with some hesitation. He still didn't know how strongly Yang Rui's decision would oppress Northern United Pharmaceuticals. In fact, there are basically no companies in China that can experience this.

In this era when companies set up research institutes, the value of research results has always been fluctuating at cost.

Unfortunately, Yang Rui is not going to discuss the cost issue with them.

How much to use is my business, the price is determined by the value.